Vamstar：2025制药、医疗科技与生物技术领域AI应用 ：解锁商业成功之道（英文版）（16页）.pdf

1、AI in Pharma,MedTech&Biotech:Unlocking Commercial SuccessReport/1AI in Pharma,MedTech&Biotech:Unlocking Commercial SuccessContents01/Executive Summary 202/Introduction 503/AI-Driven Pricing Optimisation 604/Enhancing Market Access with AI 805/Navigating Loss of Exclusivity(LOE)1006/Integrating Value

2、-Based Procurement(VBP)and ESG 1107/Tools and Technologies Powering AI in Life Sciences 1208/Conclusion and Next Steps 142AI in Pharma,MedTech&Biotech:Unlocking Commercial SuccessExecutive Summary01/Artificial intelligence(AI)has emerged as a transformative force in the life sciences industry,revolu

3、tionising commercial and procurement operations in pharmaceuticals,medtech,and biotech.By leveraging AI-driven analytics,real-world evidence(RWE),and predictive modelling,organisations can enhance efficiency,accelerate innovation,and develop data-driven strategies to address complex market challenge

4、s.These challenges include navigating fragmented regulatory landscapes,optimising pricing strategies,ensuring cost-efficient operations,and adapting to evolving value-based care models.The lifesciences industry operates in a dynamic regulatory environment,requiring companies to align innovation,affo

5、rdability,and accessibility with commercial imperatives such as pricing optimisation,market access,and lifecycle management.AI-powered platforms like Polaris from Vamstar enable organisations to break down data silos,convert fragmented information into actionable insights,and develop predictive stra

6、tegies for sustained growth.However,AI adoption must be tailored to an organisations unique challenges,making expert engagement and customised solutions essential for maximising AIs potential and securing competitive advantage.3AI in Pharma,MedTech&Biotech:Unlocking Commercial Success01/Executive Su